Have a feature idea you'd love to see implemented?
Let us know!
VVOS Vivos Therapeutics Inc
Price (delayed)
$5.06
Market cap
$24.47M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.68
Enterprise value
$19.8M
Vivos Therapeutics Inc. is a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep disordered breathing, including obstructive sleep apnea (OSA). Vivos believes that
Highlights
VVOS's EPS has soared by 57% YoY and by 19% from the previous quarter
Vivos Therapeutics's debt has decreased by 22% YoY and by 7% from the previous quarter
The net income has grown by 18% YoY but it has contracted by 4.3% from the previous quarter
Key stats
What are the main financial stats of VVOS
Market
Valuations
Earnings
Shares outstanding
4.84M
Market cap
$24.47M
Enterprise value
$19.8M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.25
Price to sales (P/S)
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.36
Revenue
$14.58M
Gross profit
$8.86M
Net income
-$12.57M
EBIT
-$12.57M
EBITDA
-$11.98M
Free cash flow
-$13.07M
Per share
Balance sheet
Liquidity
EPS
-$5.68
EPS diluted
-$5.68
Free cash flow per share
-$1.98
Book value per share
$2.25
Revenue per share
$2.2
TBVPS
$1.83
Total assets
$15.35M
Total liabilities
$7.68M
Debt
$1.64M
Equity
$7.67M
Working capital
$2.27M
Debt to equity
0.21
Current ratio
1.44
Quick ratio
1.32
Net debt/EBITDA
0.39
Margins
Efficiency
Dividend
EBITDA margin
-82.2%
Gross margin
60.8%
Net margin
-86.2%
Operating margin
-84.4%
Return on assets
-93.6%
Return on equity
-335%
Return on invested capital
-1,464.4%
Return on capital employed
-123%
Return on sales
-86.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
VVOS stock price
How has the Vivos Therapeutics stock price performed over time
Intraday
4.33%
1 week
16.22%
1 month
9.76%
1 year
-36.35%
YTD
17.95%
QTD
17.95%
Financial performance
How have Vivos Therapeutics's revenue and profit performed over time
Revenue
$14.58M
Gross profit
$8.86M
Operating income
-$12.3M
Net income
-$12.57M
Gross margin
60.8%
Net margin
-86.2%
Vivos Therapeutics's operating income has increased by 36% YoY and by 7% from the previous quarter
The company's operating margin rose by 36% YoY and by 11% QoQ
Vivos Therapeutics's net margin has increased by 19% YoY
The net income has grown by 18% YoY but it has contracted by 4.3% from the previous quarter
Growth
What is Vivos Therapeutics's growth rate over time
Valuation
What is Vivos Therapeutics stock price valuation
P/E
N/A
P/B
2.25
P/S
2.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.36
VVOS's EPS has soared by 57% YoY and by 19% from the previous quarter
The price to book (P/B) is 85% lower than the last 4 quarters average of 15.3 and 84% lower than the 5-year quarterly average of 14.1
The equity has increased by 21% since the previous quarter
VVOS's P/S is 156% above its last 4 quarters average of 0.9 but 12% below its 5-year quarterly average of 2.6
Vivos Therapeutics's revenue has increased by 4% from the previous quarter
Efficiency
How efficient is Vivos Therapeutics business performance
The company's return on equity rose by 49% QoQ and by 24% YoY
The return on invested capital is up by 36% since the previous quarter but it has declined by 19% year-on-year
VVOS's ROS is up by 19% YoY
The company's return on assets rose by 17% YoY and by 5% QoQ
Dividends
What is VVOS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for VVOS.
Financial health
How did Vivos Therapeutics financials performed over time
VVOS's total assets is 100% higher than its total liabilities
VVOS's total assets is up by 49% YoY but it is down by 3.1% QoQ
The company's total liabilities fell by 25% YoY and by 19% QoQ
Vivos Therapeutics's debt is 79% less than its equity
VVOS's debt to equity has dropped by 100% year-on-year and by 25% since the previous quarter
Vivos Therapeutics's debt has decreased by 22% YoY and by 7% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.